Viral delivery systems have emerged as a powerful method for the efficient transport of CRISPR/Cas9 components into target cells, significantly enhancing the precision and effectiveness of gene editing. By leveraging the natural ability of viruses to infect host cells, researchers can achieve high levels of transfection efficiency, making this approach particularly valuable for therapeutic applications and functional genomics.

Key Viral Vectors for CRISPR/Cas9 Delivery:

• Adeno-Associated Viruses (AAVs):
  • AAVs are small, non-pathogenic viruses that exhibit low immunogenicity, making them ideal for in vivo applications. They can efficiently deliver CRISPR components and achieve stable expression in both dividing and non-dividing cells. Recent studies have demonstrated successful gene editing using AAV vectors in models of genetic disorders, such as Duchenne muscular dystrophy.
• Lentiviral Vectors (LVs):
  • LVs are derived from HIV and can integrate into the host genome, providing long-term expression of CRISPR components. While they offer high transduction efficiency, there is a risk of insertional mutagenesis, which poses safety concerns for therapeutic applications. LVs are often used in research settings to create stable cell lines for functional studies.